Healthcare
Organon & Co.(OGN)
Live Price
Offline$13.44
-0.07% today
1Y Change
+34.40%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $3.49B
- Revenue Growth
- -2.9%
- EPS Growth
- -78.6%
- Dividend Yield
- 0.6%
Coverage: 244 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Organon & Co. (OGN) is a Healthcare stock with a market cap of $3.49B and listed on NYSE. The stock last traded around $13.44 and up 34.4% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of -2.9%, EPS growth of -78.6%, a dividend yield of 0.6%. What stands out right now is revenue -2.9%, EPS -78.6%, free cash flow -8.5% with operating margin 20.0% and ROIC 5.2%. The dividend is present but secondary, with a yield around 0.6%. Valuation is more restrained than many high-expectation growth names at P/E 18.5 and price/sales 0.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines OGN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-2.9% vs +7.6% peer median
Operating Margin
Near sector median
+20.0% vs +19.4% peer median
P/E
Below sector median
18.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -2.9% and EPS is at -78.6%, with operating margin around 20.0%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.6%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +0.2% | +0.3% | +0.3% |
2026 Feb 12, 2026 | -13.7% | +4.7% | +14.7% | -10.1% |
2025 Nov 10, 2025 | +8.6% | -2.5% | -0.8% | -9.9% |
Benchmark Edge
OGN vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OGN
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OGN Max Drawdown
-48.23%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for OGN and SPY.
Company Overview
Organon & Co.
New York Stock Exchange
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
- Leadership
- Joseph T. Morrissey Jr.
- IPO Date
- May 14, 2021
- Employees
- 10.0k
- Street Address
- 30 Hudson Street
- Mailing
- Jersey City, NJ, 07302
- Region
- Jersey City, NJ, US
- Reporting Currency
- USD
- Investor Line
- 551 430 6000
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 18.5
- EV/EBITDA
- 9.0
- Price/Sales
- 0.6
- Price/Book
- 4.6
Growth
- Revenue
- -2.9%
- EPS
- -78.6%
- Free Cash Flow
- -8.5%
Profitability
- Gross Margin
- 53.6%
- Operating Margin
- 20.0%
- Net Margin
- 3.0%
- ROE
- 25.5%
- ROIC
- 5.2%
Balance Sheet
- Debt/Equity
- 11.70
- Current Ratio
- 1.82
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.